NCT02940353已完成不适用
The TREFOIL Concept: A Clinical Investigation in the Mandible on 3 Implants With a Fixed Prefabricated Framework
Nobel Biocare10 个研究点 分布在 5 个国家目标入组 110 人开始时间: 2016年4月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 110
- 试验地点
- 10
- 主要终点
- Cumulative survival rates for the implants
研究概览
简要总结
Prospective, single cohort, multi-center study evaluating the TREFOIL concept for the treatment of edentulous or patients with failing mandibular dentition over 5 years. 90 patients (15 per centre) will be included. The subject population is at least 18 years old, in need of an implant restored full prosthesis providing sufficient bone in the interforaminal where a fixed restoration on three implants is regarded as an appropriate treatment solution. The components are TREFOIL treatment concept (implants and framework).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Obtained informed consent from the subject.
- •The subject is at least 18 years of age (passed cessation of growth) and not older than 80 years.
- •The subject is in such a physical and mental condition that a 5-year follow-up period can be carried out without foreseeable problems.
- •The subject fulfills the prerequisite that a harmonic, stable occlusal relationship can be achieved with opposing natural teeth resp. fixed or removable opposing dentition (tooth or implant based) or soft tissue born denture.
- •The subject is willing and able to comply with all study related procedures (such as exercising oral hygiene and attending all follow-up procedures).
- •The subject is compliant with good oral hygiene.
- •The subject has an edentulous mandible or failing mandibular dentition providing sufficient bone in the interforaminal where a fixed restoration on three (3) implants is regarded as an appropriate treatment solution.
- •The subject has an osseous architecture enough to receive three implants with a length of at least 11.5 mm and a diameter of 5 mm in the interforaminal (e.g. jaw volume B, C or D; inter foramina distance at least 20 mm; buccal/lingual width at least 6-7 mm, vertical height after leveling bone sufficient to receive an implant of at least 11.5 mm length).
- •The subject has a jaw curvature that fits to the prefabricated framework design.
- •Implants will be placed in healed or extraction sites (clinical stability has to be ensured).
- •The implant sites are free from infection and extraction remnants.
- •The subjects as well as the implant sites fulfill the criteria for early loading.
- •Smokers that have reduced their consumption may be included after a certain test phase (e.g. test phase for reduction from 2 to 1 packages of cigarettes should be at least 6 months).
- •Class II inter-jaw relation patients are not an
排除标准
- •per se. Based on the individual judgment of the clinician those patients may be treated.
- •Subject inclusion criteria at time of surgery
- •After bone leveling sufficient mandible bone volume in the interforaminal present for three (3) implants with a length of at least 11.5 mm and a diameter of 5 mm.
- •After bone leveling the jaw curvature does fit to the prefabricated framework.
- •The implant sites are free from infection and extraction remnants.
- •The subject as well as the implant sites fulfill the criteria for early loading.
- •Exclusion Criteria:
- •The subject is not able to give her/his informed consent of participating.
- •Health conditions, which do not permit the surgical (including anesthesia) or restorative procedure.
- •Reason to believe that the treatment might have a negative effect on the subject's overall situation (psychiatric problems), as noted in subject records or history.
- •Any disorders in the planned implant area such as previous tumors, chronic bone disease or previous irradiation.
- •Alcohol or drug abuse as noted in subject records or in subject history.
- •Smoking of more than 1 package of cigarettes per day (> 20 cigarettes or equivalent).
- •Uncontrolled diabetes, i.e. a subject with diagnosed diabetes that has a history of neglecting doctor's recommendations regarding treatment, food and alcohol intake or A1c level above 8%.
- •Bisphosphonate therapy - based on individual judgment of the clinician (if intravenously administered or too high oral doses recently before surgery and during follow-up period).
- •Pathologic occlusion, e.g. severe bruxism or other destructive habits.
- •Lack of opposing dentition or unstable occlusion.
- •Ongoing infections, endodontic or periodontal problems in opposing teeth or implants.
- •Subject shows an unacceptable oral hygiene.
- •Subject has allergic or adverse reactions to the restorative material.
结局指标
主要结局
Cumulative survival rates for the implants
时间窗: 5 years
次要结局
未报告次要终点
研究者
研究点 (10)
Loading locations...
相似试验
已完成
4 期
Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS StudyHepatitis B, ChronicNCT02195518GlaxoSmithKline213
撤回
1 期
Intralesional 5-fluorouracil Injection for the Treatment of Oral LeukoplakiaOral LeukoplakiaNCT05505539University of California, San Francisco
已完成
4 期
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMultiple SclerosisNCT01895335Sanofi1,001
招募中
2 期
A multicenter, single-arm trial to evaluate the efficacy and safety of vaccinia immune globulin therapy for patients with mpox or smallpox.JPRN-jRCTs031220744Morioka Shinichiro20
已完成
4 期
To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple SclerosisRelapsing Multiple SclerosisNCT03856619Sanofi121